Cerevance said its experimental oral Parkinson’s therapy solengepras reduced patients’ daily off-time in a Phase 3 trial, alongside other symptom improvements. The company plans to discuss a potential approval path with regulators, positioning the program as an add-on option that does not target dopamine directly.